Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
McKesson is North America's largest pharmaceutical distributor, moving ~30% of all prescription drugs in the US from manufacturers to retail pharmacies, hospitals, and health systems. The company operates a low-margin, high-volume distribution model with competitive advantages in scale economics, logistics infrastructure spanning 70+ distribution centers, and embedded relationships with major pharmacy chains (CVS, Walgreens) and manufacturers. Stock performance is driven by prescription volume growth, specialty pharma distribution (oncology, biopharma), and operating efficiency improvements.
McKesson earns thin margins (3.5% gross, 1.2% operating) on massive volume, generating returns through capital velocity and scale. Revenue is primarily cost-plus distribution fees and rebates from manufacturers, with limited pricing power but high predictability. Competitive advantages include: (1) logistics scale enabling next-day delivery to 99% of US pharmacies at lowest cost, (2) working capital efficiency with negative cash conversion cycles (paid by manufacturers before paying suppliers), (3) data assets from processing 4+ billion prescriptions annually. The business model is asset-light relative to revenue scale, with high inventory turnover (12-15x annually) and minimal capex requirements ($900M on $359B revenue).
US prescription drug volume trends (driven by aging demographics, GLP-1 adoption, biosimilar launches)
Specialty pharmaceutical distribution growth, particularly oncology and biopharma logistics (20-25% of gross profit, growing double-digits)
Manufacturer compensation agreements and generic drug pricing dynamics (impact gross margins)
Operating expense efficiency and technology investments reducing cost-to-serve
Capital allocation decisions: share buybacks ($2-3B annually), dividend growth, and M&A in higher-margin adjacencies
Vertical integration by pharmacy chains (CVS-Aetna) and payers potentially disintermediating wholesale distribution, though scale economics favor three-tier system
Drug pricing reform and potential legislation capping manufacturer prices or rebates, which could compress distributor economics
Amazon Pharmacy expansion and direct-to-consumer models bypassing traditional distribution, though specialty pharma and hospital channels remain defensible
Biosimilar adoption and loss of exclusivity for blockbuster drugs reducing high-margin specialty distribution volumes
Oligopoly structure (McKesson, AmerisourceBergen, Cardinal Health control 90%+ market) creates intense competition for manufacturer and customer contracts with limited pricing power
Customer consolidation (pharmacy chains, hospital GPOs) increasing buyer negotiating leverage and pressuring distribution fees
Technology disruption in supply chain management and inventory optimization potentially commoditizing distribution services
Negative equity position (-$18B) due to aggressive share buybacks and pension obligations creates optical concern, though strong cash generation and asset-light model support creditworthiness
Current ratio of 0.88 reflects working capital intensity and reliance on short-term financing, requiring continuous access to commercial paper and credit markets
Opioid litigation settlements ($7.4B multi-year commitment) create ongoing cash outflows through 2038, though structured payments are manageable within FCF
Debt/EBITDA around 2.5-3.0x is manageable but limits financial flexibility for large M&A without equity issuance
low - Pharmaceutical distribution is highly non-cyclical as prescription drug demand is driven by medical necessity rather than discretionary spending. Volumes correlate with demographic trends (aging population) and disease prevalence, not GDP growth. Medical-Surgical segment (~7% of revenue) has modest cyclical exposure through elective procedures, but core pharma distribution provides stability through recessions. Revenue grew through 2008-2009 financial crisis and 2020 pandemic.
Rising rates have modest negative impact through higher working capital financing costs (company carries $50-60B in inventory), though negative cash conversion cycle partially offsets this. Higher rates compress valuation multiples for low-growth, stable cash flow businesses. However, McKesson's strong FCF generation ($5.2B annually) and debt reduction capacity provide some insulation. The company benefits from floating-rate assets (receivables) repricing faster than fixed-rate liabilities in rising rate environments.
Moderate exposure through customer credit risk, primarily independent pharmacies and smaller hospital systems. McKesson maintains tight credit management with DSO around 25-30 days. Tightening credit conditions can stress smaller pharmacy customers, leading to consolidation that benefits large distributors. Manufacturer creditworthiness is critical for rebate agreements, but top 20 pharma companies represent 70%+ of volume with minimal default risk.
value - McKesson trades at 0.3x sales and mid-teens P/E despite consistent FCF generation, attracting value investors seeking stable, defensive healthcare exposure with capital return. The 61.7% one-year return reflects multiple expansion from depressed pandemic-era valuations as investors recognized earnings durability and aggressive buybacks (reducing share count 5-7% annually). Dividend yield around 0.5% is modest, but total shareholder yield (dividend + buyback) exceeds 6-8% annually. Limited growth narrative (mid-single-digit revenue, high-single-digit EPS) appeals to investors prioritizing cash generation over expansion.
low - Beta typically 0.6-0.8 reflecting defensive healthcare characteristics and non-cyclical demand. Stock exhibits lower volatility than broader market due to predictable cash flows and limited earnings surprise potential. However, regulatory headlines (drug pricing reform, opioid litigation) can create episodic volatility. The 40.6% six-month return is atypical, driven by multiple re-rating rather than fundamental volatility.
